Innate Immunity Stimulation Via TLR9 in Early AD (NCT05606341)
Phase 1 Clinical Trial of Innate Immunity Stimulation Via TLR9 in Early Alzheimer's Disease (AD)
🩺 Plain-English Summary (8th-Grade Level)
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD). There will be 3 Dose levels. An initial cohort of 13 subjects will be randomized to a Dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. An additional 13 subjects will be recruited and randomized into Dose level 2 (0.25 mg/kg vs. placebo) for 8 weeks and 13 subjects for the last Dose level 3 (0.5 mg/kg vs. placebo) for 8 weeks. The primary objective will be to assess safety and tolerability of CpG 1018.
Who can join: Review the eligibility criteria below.
Location: NYU Langone Health — New York, New York
Age range: 60 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- NYU Langone Health — New York, New York
📞 Contact the Study Coordinator
Phone: (212) 263-0771
Email: ADClinicalTrials@nyulangone.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mild Cognitive Impairment
- Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment — Toronto, Ontario
- Remote Game-based Exercise Program for Cognitive and Motor Function Improvement — Los Angeles, California
- Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) — Boston, Massachusetts
- Glutathione in Mild Cognitive Impairment — Houston, Texas
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy — Morgantown, West Virginia
- Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease — Los Angeles, California
Explore by condition: All Mild Cognitive Impairment clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.